TY - JOUR
T1 - Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
AU - Loncharich, Alexa J.
AU - Fiala, Mark A.
AU - Slade, Michael J.
AU - Vickroy, Angela
AU - Kavanaugh, Margaret
AU - Wilson, Carmen
AU - Schroeder, Mark A.
AU - Stockerl-Goldstein, Keith
AU - Vij, Ravi
AU - Sanfilippo, Kristen M.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/11
Y1 - 2023/11
N2 - Background: Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States. Materials and Methods: We retrospectively reviewed patients with newly diagnosed MM presenting at a single institution. Patients were followed for objectively diagnosed VTE events for 6 months following the start of induction therapy. Results: A total of 209 patients were included, with 69 (33%) receiving KRd and 140 (67%) receiving VRd. Overall, 18 patients (9%) had a VTE event, with 5 (7%) in the KRd cohort and 13 (9%) in the VRd cohort (P = .80). Treatment with KRd was not associated with an increased risk of VTE compared to VRd (HR 0.74; 95% CI 0.26-2.08; P = .57). Conclusion: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.
AB - Background: Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States. Materials and Methods: We retrospectively reviewed patients with newly diagnosed MM presenting at a single institution. Patients were followed for objectively diagnosed VTE events for 6 months following the start of induction therapy. Results: A total of 209 patients were included, with 69 (33%) receiving KRd and 140 (67%) receiving VRd. Overall, 18 patients (9%) had a VTE event, with 5 (7%) in the KRd cohort and 13 (9%) in the VRd cohort (P = .80). Treatment with KRd was not associated with an increased risk of VTE compared to VRd (HR 0.74; 95% CI 0.26-2.08; P = .57). Conclusion: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.
KW - Deep vein thrombosis
KW - Myeloma therapy
KW - Pulmonary embolism
KW - Thromboprophylaxis
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85167802518&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2023.07.009
DO - 10.1016/j.clml.2023.07.009
M3 - Article
C2 - 37543510
AN - SCOPUS:85167802518
SN - 2152-2650
VL - 23
SP - 825
EP - 828
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 11
ER -